Health Boards
Moberg Derma AB (STO: MOB) has entered into a distribution agreement with Menarini Group for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Menarini’s OTC Division is granted exclusive rights to market and sell Emtrix® in Italy under the trademark YouDerm Emtrix®.
“The agreement is part of our international commercialization of Emtrix®. As the leading Italian pharmaceutical group, ranked 34th in the world, Menarini is well positioned to make Emtrix® a success in Italy. Emtrix® will now be marketed in all large markets in Europe, in US and Australia”, says Peter Wolpert, President and CEO of Moberg Derma.
About Emtrix® and nail disease
Emtrix® is a topical treatment used to treat nail disease. Launched in the Nordic region in autumn 2010, it quickly became market leader. Emtrix® is a prescription free, over-the-counter product sold under the name Nalox™ in certain markets and under the name Kerasal® Nail in the U.S. Safety and efficacy have been demonstrated in several clinical studies including more than 600 patients. Emtrix® has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and increasing with age. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.
About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma’s first product Nalox™/Emtrix® - for nail disorders - became the Nordic market leader directly after launch in autumn 2010 and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The company began operations at the Karolinska Institute in Stockholm in 2006.
About Menarini Group
The Menarini Group celebrates it’s 125thAnniversary this year and is the leading Italian pharmaceutical group in the world, ranking 15thout of 4,881 companies in Europe*and 34thout of 14,051 companies in the world* (*Sources: IMS World Review 2010, IMS World Review Pack 2010 per number of companies). The Group’s 2010 global turnover was 3,031 million Euro. In 2010 the number of employees was 12,890 (91% of which graduates and technicians). The Menarini Group has always pursued two strategic objectives: Research and Internationalisation, both of which have allowed them to achieve outstanding results in today’s global market and to invest in the research of innovative drugs, making them available to patients all around the world.
Source: mobergderma.com
“The agreement is part of our international commercialization of Emtrix®. As the leading Italian pharmaceutical group, ranked 34th in the world, Menarini is well positioned to make Emtrix® a success in Italy. Emtrix® will now be marketed in all large markets in Europe, in US and Australia”, says Peter Wolpert, President and CEO of Moberg Derma.
About Emtrix® and nail disease
Emtrix® is a topical treatment used to treat nail disease. Launched in the Nordic region in autumn 2010, it quickly became market leader. Emtrix® is a prescription free, over-the-counter product sold under the name Nalox™ in certain markets and under the name Kerasal® Nail in the U.S. Safety and efficacy have been demonstrated in several clinical studies including more than 600 patients. Emtrix® has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and increasing with age. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.
About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma’s first product Nalox™/Emtrix® - for nail disorders - became the Nordic market leader directly after launch in autumn 2010 and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The company began operations at the Karolinska Institute in Stockholm in 2006.
About Menarini Group
The Menarini Group celebrates it’s 125thAnniversary this year and is the leading Italian pharmaceutical group in the world, ranking 15thout of 4,881 companies in Europe*and 34thout of 14,051 companies in the world* (*Sources: IMS World Review 2010, IMS World Review Pack 2010 per number of companies). The Group’s 2010 global turnover was 3,031 million Euro. In 2010 the number of employees was 12,890 (91% of which graduates and technicians). The Menarini Group has always pursued two strategic objectives: Research and Internationalisation, both of which have allowed them to achieve outstanding results in today’s global market and to invest in the research of innovative drugs, making them available to patients all around the world.
Source: mobergderma.com
